Articles On Actinogen Medical (ASX:ACW)

ShareCafeStocks of the Hour: HLX, ACW, GAL                    Helix Resources (ASX:HLX) provided an update this morning on the ongoing copper exploration drilling at its Canbelego Joint Venture Project located in the Cobar region of N...

10 Oct 2022 - A snapshot of the stocks on the move featuring Helix Resources (ASX:HLX), Actinogen Medical (ASX:ACW) and Galileo Mining (ASX:GAL).

Australian shares fell for a second day as US equity futures retreated ahead of inflation data and the start of a new earnings season later this week. The S&P/ASX 200 declined 105 points or 1.55 per cent to 6658 by mid-session. The i...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Benchmark finishes up after fierce struggle for buoyancy Absolutely no one shocked to learn Star’s worn out its welcome in QLD A solid arvo by little league miners was a well-timed boost It’s been a somewhat indecisive day for Aussie mark...

Blood clot programs have taken the spotlight recently as new discoveries made Two ASX health stocks are in the blood clot space Top performing ASX healthcare stocks in the past month Blood clots were top of biotech news this week after re...

Acting out your dreams could be a sign of a neurological disease, a study finds ASX-listed Pharmaxis to launch a study on iRBD patients who are at risk of Parkinson’s Stockhead reaches out to Pharmaxis CEO, Gary Phillips A rare sleep diso...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

Actinogen Medical (ASX:ACW) has provided further information on the timing and design of its upcoming biomarker study in patients with mild Alzheimer’s disease.

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

An additional news report on the recommendation, valuation, forecast and opinion changes for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now added The Au...

Actinogen Medical (ACW) finalises the designs for its planned phase two trials in Alzheimer’s Disease (AD) and Major Depressive Disorder (MDD) The trials will be testing the company’s lead compound, Xanamem, as a new therapy for AD and dep...

ASX Health stocks endure another topsy-turvy week ending in red Monash IVF makes two key purchases to expand its foothold in fertility sector Actinogen Medical to push ahead with trial into treatment of early Alzheimer’s disease. Healthca...

Highlights The ASX Small Ordinaries index surged 1.59% to 2,987 by 12:30 PM AEST today. OZM, SBW and ACW are three ASX penny stocks racking up high gains today. Investors must do proper due diligence before investing in penny stocks....

Actinogen (ACW) announced it will prioritises its phase two trials in Alzheimer’s disease and depression Following results in the company’s recent double-blind XanaMIA Part A trial, Actinogen conducted a reassessment of its priorities and...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

Actinogen Medical (ACW) confirms positive topline results from its XanaMIA Part A trial, meeting primary safety, pharmacodynamic and efficacy endpoints Results from the trial confirm Xanamem’s ability to enhance cognition and are consisten...

Stockhead’s Top 10 at 10, published at 10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The ASX will head into the Anzac day long weekend on a slightly sour note following a Friday selloff. For the microcap Emerging Companies index, it was a ~1.5% fall on the day — but that didn’t stop another triple-digit percentage return, t...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Highlights Biotechnology companies research living organisms to develop drugs and other products. Investing in biotechnology stocks require due diligence and caution to make a profit and avoid loss. The S&P/ASX 200 Health Care ind...

Telehealth was already a growing space even before the pandemic, but COVID had launched it into the mainstream. At the height of the pandemic in 2020, data from Research and Markets showed that 76% of hospitals in the US were using teleheal...

The ongoing lawsuit involving Johnson & Johnson (J&J)’s talc products took a controversial turn in the courts this week. The healthcare giant is currently staring down 38,000 claims that its talc products (including the famous baby...

At the time of writing, the ASX 200 Health Index (XHJ) is down 2%, while the benchmark ASX 200 is also falling by 0.75%. The path is now open for pharma distributor Australian Pharmaceutical Industries (ASX: API) to be acquired by Wesfarmer...

Actinogen Medical (ACW) completes final participant visits for the XanaMIA Part A trial which the company says will provide analysis of the effects of its Xanamem technology Xanamem is designed as an oral therapeutic for Alzheimers Disease...

Actinogen Medical (ACW) appoints a trial manager for its XanaFX phase-two trial in adolescent boys and young adults with Fragile X Syndrome (FXS) Clinical research organisation Worldwide Clinical Trials will manage the recruitment of parti...

Motion analysis device maker dorsaVi (ASX:DVL) has been awarded the internationally recognised ISO 27001 certification, verifying the data security standards for the company . The ISO 27001 standard specifies advanced information security a...

Returns in the ASX healthcare basket were fairly robust throughout 2021. Sector earnings saw a return to pre-COVID levels as patient and service volumes began to normalise as well. The S&P/ASX 200 Health Care Index (ASX: XHJ) has clim...

At the time of writing, the ASX XHJ Healthcare index is up 5.55% over the last five trading days, beating the ASX200 benchmark index which was up 2.8% for the period. Here’s a table showing how ASX-listed healthcare stocks have been perform...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

The life sciences sector has emerged into the spotlight ever since the pandemic began. In the US, the share prices of major vaccine-producing companies have surged astronomically as COVID-19  ravaged the world. Nasdaq-listed BioNTech, which...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

The Actinogen Medical Ltd (ASX: ACW) share price soared today after the company announced a partnership with Oxford University. Shares in the biotechnology company finished the day at 13 cents, up 8.7% on the previous close. Actinogen is...

Actinogen Medical (ACW) is collaborating with Oxford University researchers to investigate Xanamem and a condition called mild autonomous cortisol secretion (MACS) MACS is associated with an over-production of the stress hormone cortisol a...

The ASX 200 Health Index (XHJ) is down by 0.80% at the time of writing, compared to the broader index which is down by 0.40%. The stock price of Neuren Pharmaceuticals (ASX:NEU) is up 100% this morning after the company announced its North...

ASX recovered some lost ground in arvo trade but still finished 0.54% down, as markets continue to be shaken by the discovery of the omicron variant of COVID-19 and falling oil prices. Resources and tech managed to finish in the green – by...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Actinogen Medical (ACW) places its shares in a trading halt to finalise the details of an upcoming capital raising The company’s shares will remain in the halt until November 25 or when more details are released, whichever occurs first O...

The Australian bourse recouped most of yesterday’s losses despite tech stocks dropping again, this time by 3.49%. The ASX 200 rose 0.78%, closing at 7,411 points, with the gains driven by the resources and energy sectors, which gained 2.3%...

Bell Potter has been tapped to help Actinogen Medical to support the expansion of its clinical trials for leading drug candidate Xanamem.

The ASX closed down again today in spite of resources and tech gaining over 1%. The ASX 200 fell 0.24%, closing at 7,434 points. Despite the gains in resources and tech most other sectors fell with financials, property and energy retreating...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) has dropped back into the red. At the time of writing, the benchmark index is down 0.15% to 7,442.1 points. Four ASX shares that are falling more than most today are listed below. He...

Shares in Australian biotech Actinogen Medical Ltd (ASX: ACW) are crawling lower today, currently trading down 15.79% at 16 cents apiece. Investors are selling Actinogen shares today despite the company receiving clearance from the US Foo...

Highlights  Despite going through a rough patch, few ASX shares have gained over 400% from the prior year. IHL’s revenue increased to AU$1.89 million from AU$604,884 in FY2020. IHL, CXL, ACW, NVX and LTR delivered 213%, 431%, 567%, 51...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

The ASX 200 rose 0.41% to close at 7,535 while the ASX Emerging Companies Index gained another 1.36% to close at 2,362 points. All sectors were in the green except energy and utilities which lost 1.44% and 1.19%. The best performing sectors...

Local markets continued their strong form on Wednesday as the ASX rose for the third straight session. Reporting season threw up some big-name winners as markets responded to the latest round of full-year results. While the ASX 200 edged hi...